Enlivex Therapeutics (NASDAQ:ENLV) Price Target Raised to $7.00

Posted by Donald Scott on Mar 27th, 2025

Enlivex Therapeutics (NASDAQ:ENLV – Free Report) had its target price increased by HC Wainwright from $6.00 to $7.00 in a report released on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Enlivex Therapeutics’ FY2025 earnings at ($0.59) EPS.

Separately, D. Boral Capital reissued a “buy” rating and set a $13.00 price objective on shares of Enlivex Therapeutics in a research note on Monday, March 3rd.

Get Our Latest Report on Enlivex Therapeutics

Enlivex Therapeutics Stock Down 3.7 %

ENLV stock opened at $1.05 on Monday. Enlivex Therapeutics has a twelve month low of $0.81 and a twelve month high of $4.59. The company has a market cap of $22.48 million, a P/E ratio of -1.07 and a beta of 1.11. The business’s fifty day moving average is $1.10 and its 200-day moving average is $1.24.

Institutional Investors Weigh In On Enlivex Therapeutics

Hedge funds have recently modified their holdings of the business. Two Sigma Securities LLC acquired a new position in shares of Enlivex Therapeutics in the 4th quarter valued at approximately $26,000. Renaissance Technologies LLC lifted its stake in Enlivex Therapeutics by 112.6% in the fourth quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock valued at $186,000 after buying an additional 84,203 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in shares of Enlivex Therapeutics in the fourth quarter valued at approximately $742,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

About Enlivex Therapeutics

(Get Free Report)

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.